We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,237

Will Physician Payment Sunshine Act data usher in a new era of False Claims Act litigation?
  • Reed Smith LLP
  • USA
  • April 10 2014

While attention has been focused on Medicare physician payment data released by CMS yesterday, upcoming Sunshine Act data will shine a new spotlight


Insurance issues: Summer 2016
  • CMS Cameron McKenna
  • European Union, United Kingdom
  • August 11 2016

The European Court of Justice handed down its judgment on 17 February 2016 in the case of Air Baltic Corporation AS v Lietuvos Respublikos


Boston Scientific prevails in securities fraud lawsuit
  • Winston & Strawn LLP
  • USA
  • August 22 2011

On August 15th, the First Circuit addressed what adverse events associated with medical devices an issuer must disclose, affirming the entry of summary judgment dismissing a Rule 10b-5 securities fraud lawsuit


State prosecutors file consumer protection lawsuit against Toyota
  • Shook Hardy & Bacon LLP
  • USA
  • March 18 2010

California state prosecutors have reportedly sued Toyota Motor Corp., alleging it engaged in fraud by concealing evidence of dangerous motor vehicle defects


Matrixx Securities fraud case could affect product liability law
  • Squire Patton Boggs
  • USA
  • December 10 2010

Sometimes the most significant changes in the law come from unexpected places


Senate adopts food safety crime bill
  • Shook Hardy & Bacon LLP
  • USA
  • April 22 2011

The U.S. Senate has approved a bill (S. 216) designed to “strengthen criminal penalties for companies that knowingly violate food safety standards and place tainted food products on the market,” according to the legislation’s sponsor, Senator Patrick Leahy (D-Vt


GlaxoSmithKline LLC to pay the largest health care fraud settlement in U.S. history
  • Bricker & Eckler LLP
  • USA
  • July 3 2012

The United States Department of Justice (DOJ) announced on July 2, 2012, that drug maker GlaxoSmithKline LLC (GSK) has agreed to plead guilty and pay $3 billion the largest penalty ever paid by a pharmaceutical company to resolve its criminal and civil liability for off-label promotion of several drugs, failure to report safety data, and false price reporting practices


FDA to increase enforcement actions against corporate officials
  • Faegre Baker Daniels LLP
  • USA
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions


Indictment of former GlaxoSmithKline in-house attorney highlights risks and provides lessons for handling document requests in government investigations
  • Jenner & Block LLP
  • USA
  • November 23 2010

A former in-house counsel at pharmaceutical company GlaxoSmithKline ("GSK"), Lauren Stevens, was indicted earlier this month for obstruction of a proceeding, false statements, and falsifying or concealing documents for her role in responding to a document request from the Food and Drug Administration ("FDA"


New indictment of in-house counsel indicates enhanced efforts to hold corporate executives accountable for food and drug law violations
  • Fish & Richardson PC
  • USA
  • November 15 2010

This year, both the Food and Drug Administration (FDA) and Department of Justice have repeatedly signaled to the pharmaceutical and medical device industries that they should expect an increase in the criminal prosecution of individuals for alleged violations of the food and drug laws, with the stated goals of increasing deterrence and greater compliance